Natera (NTRA) announced that the federal District Court for the Middle District of North Carolina has issued a preliminary injunction, effective immediately, enjoining the RaDaR assay from NeoGenomics (NEO). The injunction bars NeoGenomics from “making, using, selling, or offering for sale in the United States… the accused RaDaR assay,” or “any assay or product not more than colorably different” from the NeoGenomics RaDaR assay. In addition, the order prohibits NeoGenomics from “promoting, advertising, marketing, servicing, distributing or supplying” RaDaR to induce infringement by others. NeoGenomics may continue to offer RaDaR for existing patients and for clinical trials, studies or projects already in process.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera begins study on benefits of Signatera’s method for ctDNA quantification
- Natera initiated with bullish view at Guggenheim, here’s why
- Natera initiated with bullish view at Wolfe Research, here’s why
- Natera initiated with bullish view at Wolfe Research
- Natera price target raised, named a best idea for 2024 at TD Cowen
